Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized anti-cancer and palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics is developing natural cannabinoid formulations based on diagnostic procedures designated for the treatment of cancer and its side-effects . We are currently engaged in a clinical study, in Israel, on Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients. Our path to fight cancer is based on the engagement of personalized medicine related technology such as High Throughput Screening Technology (HTS) on cancer cell lines and CTC drug sensitivity tests on liquid biopsies.